Where Intellia Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the last quarter, 9 analysts rated Intellia Therapeutics (NASDAQ:NTLA) with an average price target of $70.78, implying an upside from the current price of $43.61. The current average has decreased by 5.21% from the previous average price target of $74.67.
June 13, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics (NASDAQ:NTLA) has an average price target of $70.78 from 9 analysts, implying an upside from the current price of $43.61. The current average has decreased by 5.21% from the previous average price target of $74.67.
The average price target of $70.78 from 9 analysts implies an upside potential for Intellia Therapeutics (NASDAQ:NTLA) from its current price of $43.61. The decrease in the average price target by 5.21% from the previous average of $74.67 may indicate a slightly lower optimism among analysts, but the overall sentiment remains positive. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100